Therapeutic TBX2 and TBX3 antagonist peptides and their derivatives for the treatment of multiple cancers 抑制腫瘤細胞生長的抗 TBX2 和 TBX3 多肽藥物及其衍生物
- 总结
- 本发明提供一种利用多肽及其衍生物阻断肿瘤细胞增殖 的方法，其中多肽的核酸序 列 来自多种肿瘤细胞中高表达 TBX2 和 TBX3 的 cDNA 片段。所述的多肽 TAP21 含有 83 个氨基酸，分子量约为９kDa 。本发明还提供一种利用表达载体在大肠杆菌中表达并且纯化多肽的方法。与现有的抗癌药一个显著不同点在于，该多 肽由极强的靶性，对正常德 组 织和细胞无毒副作用。该多肽以小分子多肽形式直接导入 肿瘤细胞，它能明显抑制肿 瘤 细胞增殖，降低癌基因的表达，促进肿瘤细胞迅速凋亡，是肿瘤治疗过程中的潜在药物。
This invention provides effective peptides and their derivatives to block tumor growth. These peptides functions as antagonist of TBX2 and TBX3, which are highly expressed in multiple cancer cells and play important roles in carcinogenesis and maintenance of cancer cell growth. The peptides are about 9 kDa, expressed in E.Coli and purified by affinity chromatography. Unlike other anticancer drugs, our peptides are not toxic for normal cells and specifically inhibition tumor growth by induction of cancer cell death rapidly; therefore, these peptides display great potential for anticancer treatment in clinic.
Page 1 of 1
- 申请号码
- 09/MED/340/ITF
- 其他
- Inventor(s): Professor Ming-liang HE, Stanley HO Centre for Emerging Infectious Diseases
Patent Status: Chinese Patent Pending Licensing Status: Available for licensing
- 国家/地区
- 香港
欲了解更多信息，请点击 这里
